Al Roker has spent decades telling television viewers when storms are approaching. In November 2020, however, the longtime NBC personality delivered a far more personal forecast: he had been diagnosed with prostate cancer.
The announcement was serious but hopeful. Roker said doctors had found the disease early, although testing suggested it was somewhat aggressive. He would temporarily step away from the Today show to undergo surgery and recover. By discussing the diagnosis publicly, he also turned an intensely private health crisis into an important conversation about prostate cancer screening, early detection, and the disproportionate risks facing Black men.
How Al Roker’s Prostate Cancer Was Discovered
Roker announced his diagnosis on November 6, 2020, when he was 66 years old. He did not seek medical care because of pain, urinary problems, or another obvious warning sign. The cancer was discovered after routine bloodwork during an annual physical showed an elevated prostate-specific antigen, commonly called PSA.
An elevated PSA level does not automatically mean cancer. PSA can also rise because of benign prostate enlargement, inflammation, infection, recent medical procedures, and other factors. In Roker’s case, however, the result prompted further evaluation rather than being tucked into a file and forgotten like a gym membership purchased in January.
From an Elevated PSA to a Confirmed Diagnosis
Roker subsequently underwent imaging and a prostate biopsy. The biopsy confirmed prostate cancer with a Gleason score of 7 or higher, indicating a tumor that required careful attention. He described the situation as a mixture of good and bad news: the cancer appeared to have been caught early, but it also showed aggressive characteristics.
The Gleason scoring system helps doctors estimate how abnormal prostate cancer cells look under a microscope. It is used with other informationincluding PSA levels, imaging findings, the number of biopsy samples containing cancer, and evidence of spreadto determine the cancer’s risk category and guide treatment.
A Gleason score is not a fortune cookie that predicts one inevitable outcome. Two patients with apparently similar scores may receive different recommendations because their ages, overall health, tumor volume, imaging results, personal priorities, and cancer stages differ.
Why Roker Chose Prostate Cancer Surgery
After reviewing his options with specialists, Roker chose a radical prostatectomy. The procedure removes the prostate gland and generally includes the seminal vesicles; nearby lymph nodes may also be removed when doctors need to check for cancer spread.
Roker underwent robotic-assisted surgery at Memorial Sloan Kettering Cancer Center in November 2020. His surgeon was Dr. Vincent Laudone, a urologic surgeon who has treated many patients with prostate cancer. Robotic surgery still depends on the judgment and skill of the surgeonthe robot does not stroll into the operating room, crack its mechanical knuckles, and take over.
What the Postoperative Findings Showed
Following the operation, Roker reported that the surgical pathology showed no evidence that the cancer had spread beyond the prostate. That was encouraging news because localized prostate cancer is generally much easier to treat successfully than disease that has reached distant organs.
He returned to the Today studio approximately two weeks after surgery and said he was feeling well. A quick television comeback should not be treated as a standard recovery schedule, however. Recovery varies according to the operation, the patient’s health, complications, job demands, and individual healing process. Someone whose work involves lifting construction materials should not compare his timeline with that of a broadcaster seated behind a desk.
Understanding Prostate Cancer
The prostate is a small gland located below the bladder and in front of the rectum. It surrounds part of the urethra and contributes fluid to semen. Although it is often described as walnut-sized, it commonly grows larger with age.
Prostate cancer develops when cells in the gland begin growing abnormally. It is one of the most frequently diagnosed cancers in American men, second only to skin cancer. An estimated one in eight men in the United States will receive a prostate cancer diagnosis during his lifetime.
Not all prostate cancers behave alike. Some grow so slowly that they may never threaten a patient’s life. Others progress quickly and can spread to lymph nodes, bones, or additional organs. This wide range of behavior is why an individualized risk assessment matters more than simply hearing the word “cancer” and assuming every case follows the same script.
Can Prostate Cancer Develop Without Symptoms?
Yes. Early prostate cancer often produces no noticeable symptoms, as Roker’s experience demonstrated. When symptoms occur, they may include difficulty beginning urination, a weak or interrupted stream, frequent nighttime urination, blood in urine or semen, or trouble emptying the bladder.
Those symptoms do not necessarily indicate cancer. Benign prostate enlargement and other noncancerous conditions can cause similar problems. Advanced prostate cancer may produce bone pain, weakness, or unintentional weight loss, but waiting for such symptoms before seeking care can allow a dangerous tumor more time to spread.
What the PSA Test Canand CannotTell You
A PSA test measures the amount of prostate-specific antigen in the blood. It can help identify men who may need additional evaluation, but it cannot diagnose prostate cancer by itself.
A higher result may lead to repeat testing, a physical examination, magnetic resonance imaging, specialized blood or urine tests, or a biopsy. Doctors may also examine how the PSA level changes over time instead of making a decision from a single number.
Screening Has Benefits and Possible Harms
PSA screening can uncover an aggressive cancer before it causes symptoms or spreads. That potential benefit must be balanced against false-positive results, anxiety, biopsy complications, overdiagnosis, and treatment of slow-growing cancers that might never have caused harm.
For that reason, major medical organizations recommend shared decision-making rather than treating screening as an automatic ritual for every man. Age, race, family history, life expectancy, inherited genetic changes, previous PSA results, and personal preferences should all be part of the discussion.
The U.S. Preventive Services Task Force advises men ages 55 to 69 to make an individual decision about PSA screening after discussing its potential benefits and harms with a clinician. It recommends against routine PSA-based screening in men 70 and older. Other organizations encourage earlier conversations for people at increased risk, so patients should ask which guidance applies to their circumstances.
Why Roker’s Message Was Especially Important for Black Men
Roker deliberately used his national platform to highlight racial disparities in prostate cancer. Current U.S. estimates indicate that Black men are about 1.7 times more likely to be diagnosed with the disease and approximately twice as likely to die from it as White men. Roughly one in six Black men is expected to develop prostate cancer during his lifetime.
No single explanation accounts for this disparity. Researchers continue to study tumor biology and inherited risk, while health experts also point to unequal access to preventive care, high-quality treatment, insurance, specialist services, and clinical trials. Delayed diagnoses and medical distrust shaped by historical and ongoing discrimination may contribute as well.
More recent evidence-based guidance from the Prostate Cancer Foundation recommends that Black men who choose screening consider obtaining a baseline PSA test between ages 40 and 45. The appropriate schedule after that depends on the result, health status, family history, and conversation with a qualified clinician.
Family History Also Changes the Conversation
A man may face increased risk if his father, brother, or son has had prostate cancer, particularly when the relative was diagnosed at a younger age. A family history of certain breast, ovarian, pancreatic, or colorectal cancers may also suggest inherited genetic changes relevant to prostate cancer risk.
Patients should share cancer history from both sides of the family. Genes are famously uninterested in whether a relative belongs on the maternal or paternal branch of the family tree.
Prostate Cancer Treatment Is Not One-Size-Fits-All
Roker underwent surgery because his clinical findings suggested that prompt treatment was appropriate. That does not mean surgery is automatically the best choice for everyone diagnosed with prostate cancer.
Active Surveillance
Active surveillance may be suitable for selected low-risk cancers that are unlikely to grow quickly. It involves scheduled PSA tests, examinations, imaging, and sometimes repeat biopsies. Surveillance is active medical managementnot ignoring the tumor and hoping it becomes bored.
Surgery and Radiation Therapy
Radical prostatectomy and radiation therapy are common treatments for localized prostate cancer. Both can provide effective cancer control in appropriately selected patients. The choice may depend on tumor risk, urinary function, age, other medical conditions, treatment availability, and the patient’s feelings about potential side effects.
Possible long-term effects of prostate surgery include urinary incontinence and erectile dysfunction. Radiation can also affect urinary, sexual, and bowel function. Recovery and side-effect patterns differ, making a detailed discussion with a urologist, radiation oncologist, and medical oncologist valuable before treatment begins.
Treatment for Advanced Disease
When prostate cancer has spread, treatment may involve hormone therapy, chemotherapy, targeted medicines, immunotherapy, radiopharmaceuticals, or combinations of several approaches. Modern treatments can often control advanced disease for significant periods, although metastatic prostate cancer remains much harder to cure.
Recovery and Follow-Up After Roker’s Surgery
After a prostatectomy, doctors use PSA testing to watch for signs that cancer may remain or return. Because the prostate has been removed, PSA is generally expected to fall to a very low or undetectable level. A later increase may prompt additional evaluation, but the meaning of any result should be interpreted by the treating team.
Roker later reported no evidence of disease and continued regular PSA monitoring. In 2025, while marking the fifth anniversary of his surgery, he said his PSA remained negligible and that he was doing well. His experience illustrates that reaching treatment day is not the end of cancer care; follow-up testing and survivorship support remain important.
He also continued encouraging menparticularly men of colorto discuss PSA testing with their doctors. That advocacy may prove to be one of the most influential parts of his story. A familiar television figure can sometimes start a health conversation that a stack of waiting-room pamphlets never manages to begin.
Experiences and Practical Lessons Related to a Prostate Cancer Diagnosis
Roker’s public journey reflects several experiences commonly described by patients and families. These observations are not substitutes for personalized medical advice, but they can help people prepare for the emotional and practical realities surrounding prostate cancer.
The Diagnosis May Feel Shocking Even When It Is Early
The word “early” can sound reassuring to everyone except the person who has just heard “you have cancer.” Patients may experience fear, disbelief, anger, or an urgent desire to make a treatment decision before they have finished processing the diagnosis.
It can help to bring a trusted person to appointments, take notes, and ask whether the conversation may be recorded. Patients should request plain-language explanations of the cancer stage, Grade Group or Gleason score, imaging results, and available treatments. A second medical opinion is also reasonable, especially when several options could offer similar cancer control.
Choosing Treatment Can Be Emotionally Complicated
Many patients must compare cancer-control goals with possible effects on urinary continence, sexual function, fertility, bowel function, and daily life. These topics may feel awkward, but awkwardness is a poor medical strategy. Asking direct questions before treatment allows patients and partners to form realistic expectations.
Useful questions include how often the medical center performs the proposed treatment, what complications are most common, how recovery is managed, and what rehabilitation services are available. Patients may also ask how surgery, radiation, or surveillance could affect future treatment choices.
Recovery Is Usually a Process, Not a Television Montage
After prostate surgery, patients may temporarily use a urinary catheter and experience fatigue, soreness, constipation, or urinary leakage. Walking is often encouraged according to the surgeon’s instructions, while heavy lifting and strenuous activity may be restricted.
Pelvic-floor exercises can support continence recovery when taught and timed appropriately. Sexual rehabilitation may involve medication, devices, counseling, or other treatments. Improvement can take months, and comparing one patient’s recovery with another’s may create unnecessary frustration.
Partners and Caregivers Need Information Too
A partner may help manage appointments, medications, meals, transportation, and postoperative supplies while privately carrying considerable fear. Clear communication is essential. Patients do not need to remain relentlessly cheerful, and caregivers do not need to perform superheroism without rest.
Support groups, oncology social workers, sexual-health specialists, and counseling services can provide practical help. Financial navigators may assist with insurance concerns, travel costs, or time away from work.
Follow-Up Tests Can Trigger “Scanxiety”
Even after successful treatment, upcoming PSA tests may revive the emotions of diagnosis day. Some survivors cope by scheduling tests early in the week, asking when results will be released, planning a calming activity, and discussing anxiety with their medical team.
Roker’s continuing PSA monitoring is a reminder that survivorship includes both gratitude and uncertainty. Good follow-up care addresses emotional health, urinary and sexual side effects, physical activity, heart health, and quality of lifenot merely a laboratory number.
Sharing a Story Can Prompt Someone Else to Act
Not every patient wants to discuss cancer publicly, and privacy deserves respect. Yet Roker’s openness showed how one personal account can encourage thousands of families to talk about screening, family history, and access to care.
The practical lesson is simple: know your risk, keep routine medical appointments, and ask informed questions. Prostate cancer may not announce itself with symptoms. Sometimes the most valuable warning arrives quietly in a blood test.
Conclusion
Al Roker’s prostate cancer diagnosis began with routine testing rather than noticeable symptoms. An elevated PSA led to imaging, a biopsy, and the discovery of an early but aggressive cancer. He underwent a radical prostatectomy, received encouraging postoperative results, returned to television, and continued long-term monitoring.
His experience does not establish a universal screening or treatment plan. It does demonstrate why men should understand their personal risk and discuss PSA testing with a healthcare professional. That conversation may be particularly important for Black men and those with a strong family history.
Early detection is not a guarantee, and screening has genuine limitations. Still, an informed discussion is far better than avoiding the subject until symptoms force it onto the agenda. Forecasts are imperfect, as any meteorologist knows, but having reliable information can help people prepare for what comes next.
